688185 CanSino Biologics Inc.
- 52.09
- +0.29+0.56%
CanSino Biologics Inc. News
Cansino (688185.SH): Register of A-share shareholders on May 10, with 21,183 holders
Gelonghui, May 13 | Cansino (688185.SH) said on the investor interactive platform that according to the company's A-share shareholder register issued by China Securities Registration and Settlement Co., Ltd. on May 10, 2024, the number of holders is 21,183.
Changes in Hong Kong stocks | Cansino Biotech (06185) rose more than 6% in the intraday period, UBS says MCv4 business revenue may increase 50% this year
The Zhitong Finance App learned that Cansino Biotech (06185) rose more than 6% in the intraday period. As of press release, it had risen 4% to HK$20.8, with a turnover of HK$24.9353 million. UBS published research stating that as the number of births falls further, the market focus will continue to shift from child vaccines to adult vaccines. At the same time, it is predicted that, driven by the increasing penetration rate of the MCv4 vaccine, Cansino's MCv4 business revenue will increase by 50% in 2024. According to the bank, the penetration rate of the Cansino Biotech MCV4 vaccine is relatively low, and the launch of the new product brings rich catalysts, setting the target price of Cansino H shares at
Cansino Biotech (06185.HK) Purchases Structured Deposits
Glonghui, May 8, 丨 Cansino Biotech (06185.HK) announced that on May 8, 2024, the company and Bohai Bank signed a structured deposit agreement VI with Bohai Bank. Based on this, the company agreed to purchase a structured deposit with a principal amount of RMB 200 million from Bohai Bank.
Changes in Hong Kong stocks | Cansino Biotech fell more than 5%, and its loss increased to 170 million yuan in the first quarter. It plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Cansino Biotech (06185) fell by more than 5%. As of press release, it was down 5.11% to HK$17.84, with a turnover of HK$15.417,300.
Cansino Biotech (06185) plans to transfer AD5-eBoV and its global commercialization rights to the drug Cansino
Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, approximately...
康希諾生物：截至2024年3月31日止三個月的第一季度報告
Changes in Hong Kong stocks | Cansino Biotech (06185) is now up more than 4% Hib vaccine clinical trial approved, PBPV clinical trial has achieved positive initial results
The Zhitong Finance App learned that Cansino Biotech (06185) is now up more than 4%, with a cumulative increase of more than 18% during the month. As of press release, it rose 4.1% to HK$18.8, with a turnover of HK$17.022,600. According to the news, Cansino Biotech recently announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most important pathogens of acute lower respiratory infections in children. Cansino Biotech also previously announced the recombinant pneumonia developed by the company
康希諾生物：2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
The biomedical sector gained strength in the afternoon, and Pharmaceutical Federation (02268) rose 8.59%. Institutions say the industry still has structural growth this year
Jinwu Financial News | The biomedical sector gained strength in the afternoon, with Pharmaceuticals (02268) up 8.59%, Rongchang Biotech (09995) up 6.53%, Cinda Biotech (01801) up 6.48%, Cansino Biotech (06185) 6.4%, Viva Biotech (01873) 5.88%, Hehuang Pharmaceutical (00013) up 5.58%, and Kang Fang Biotech (09926) up 5.41%. Huaxin Securities said that the growth of the industry in the first quarter of 2024 was clearly affected by the base for the same period, such as retail pharmacies, POCT, etc., and the outlook is for the whole of 2024.
Changes in Hong Kong stocks | Cansino Biotech (06185) once rose nearly 6% and freeze-dried Haemophilus influenzae type b conjugate vaccine was approved for clinical trials
At one point, Cansino Biotech (06185) rose nearly 6%. As of press release, it rose 4.69% to HK$18.32, with a turnover of HK$8.3079 million.
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine
Cansino Biologics (HKG:6185) received approval from the National Medical Products Administration of China to begin clinical trials for its Haemophilus influenzae Type B (Hib) Conjugate Vaccine, a Mond
Cansino Biotech (06185.HK): Freeze-dried Haemophilus influenzae type b conjugate vaccine approved for clinical trials
Gelonghui, April 22丨Cansino Biotech (06185.HK) announced that the freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine developed by the company has been approved by the China National Drug Administration and can carry out relevant clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most common pathogens of acute lower respiratory infections in children. It is divided into capsular type and non-perpendicular type, both of which can cause infection. Non-capsular strains often cause diseases such as otitis media and sinusitis. It is mainly caused by nasopharyngeal colonizing bacteria spreading to nearby sites; infections secondary to bloodstream attacks are usually caused by capsular strains. There is a capsular
Cansino (688185.SH): Freeze-dried Haemophilus influenzae type b conjugate vaccine obtained drug clinical trial approval notice
Gelonghui, April 22丨Cansino (688185.SH) announced that it recently received the “Drug Clinical Trial Approval Notice” for the freeze-dried Haemophilus influenzae type b conjugate vaccine (“Hib vaccine”) approved and issued by the State Drug Administration. The Hib vaccine developed by the company is a covalent combination of purified Hib capsular polysaccharide and tetanus toxoid protein. It is expected to induce humoral immunity against Hib after vaccination and provide protection to vaccinators.
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results
Cansino Biologics (HKG:6185) said it received positive preliminary results from Phase I clinical trials of its protein-based pneumococcal vaccine, according to a Sunday filing on the Hong Kong bourse.
Cansino Biotech: The recombinant pneumococcal protein vaccine obtained positive initial phase I clinical results
Cansino Biotech (06185) announced that the recombinant pneumococcal protein vaccine developed by the company obtained positive initial results in phase I (including phase Ia and phase Ib) clinical trials. PBPV is a globally innovative pneumonia vaccine under development. Unlike the 23-valent pneumococcal polysaccharide vaccine and the 13-valent pneumococcal polysaccharide conjugate vaccine, it is not a serotype-specific vaccine. It mainly uses antigens based on pneumococcal surface protein A (pSpA, a highly conservative protein expressed by almost all pneumococci). Compared with PPV23 and PCV13 currently on the market, PBPV has a higher serum coverage rate.
Cansino Biotech (06185.HK) plans to hold a board meeting on April 29 to approve the first quarter results
Glonghui, April 17, 丨 Cansino Biotech (06185.HK) announced that the board of directors meeting will be held on April 29, 2024 (Monday) to consider and approve (among other things) the first quarter results of the company and its subsidiaries for the three months ended March 31, 2024 and their announcements.
康希諾生物：董事會會議通告
Changes in Hong Kong stocks | Cansino Biotech (06185) rose nearly 6% in the afternoon, MCV series products are expected to usher in further volume
The Zhitong Finance App learned that Cansino Biotech (06185) rose nearly 6% in the afternoon. As of press release, it had risen 4.54% to HK$17.96, with a turnover of HK$11.644,000. CITIC Construction Investment said that in 2023, Cansino Biotech's profit side was affected by factors such as a sharp drop in COVID-19 vaccine revenue, the reduction in returns, and the inclusion of redundant production capacity in operating costs and asset impairment. It is expected that this part of the impact will be drastically reduced in 24. Combined with revenue growth and cost scale control, the overall loss is expected to narrow drastically. The bank pointed out that MCV series products, as the company's main products, are being promoted in various regions
Cansino Biotech buys 60 million yuan of structured deposits from Bohai Bank
Cansino Biotech (06185) announced that on April 11, 2024, the company and Bohai Bank signed a structured deposit agreement V with Bohai Bank. Based on this, the company agreed to purchase a structured deposit with a principal amount of RMB 60 million from Bohai Bank.
Analysis
Price Target
No Data
